A novel coronavirus (2019-nCoV) was identified as the cause associated with emerging pneumonia (COVID-19) detected in Wuhan on January 7, 2020. Because the number of patients has risen rapidly worldwide, COVID-19 has become a thorny international public health event. As of Mar 24, 2020, China has cumulatively diagnosed 81,747 cases and 147 new cases, while the number of cases in other countries has grown rapidly to a total of 291,070 confirmed cases and 22,027 new cases identified every day, as of this writing. Emerging studies suggest that COVID-19 preferentially afflicts the elderly, particularly those with chronic comorbidities ([@bib1],[@bib2]). However, the clinical profiles of COVID-19 in refractory heart failure patients is unknown. This paper reports the clinical features in a group of end-stage heart failure patients with COVID-19, providing strong evidence of cardiac injury by the virus.

This study was approved by the institutional review board of Union Hospital, Tongj Medical College. All hospitalized patients in the authors' department were screened for 2019-nCoV infection by nucleic acid test and chest computed tomography scans. Demographic information and clinical, biochemical, and radiological characteristics and treatment and outcome data were retrieved from electronic medical records. According to China Centers for Disease Control protocol, duplex reverse transcription-polymerase chain reaction or serum antibody test was performed to detect 2019-nCoV infection in throat swabs or blood samples. If respiratory samples tested positive by both open reading frame 1aboratory gene and nucleocapsid protein gene, the case was considered laboratory-confirmed. Presumed hospital-related transmission was suspected if hospitalized patients in the same wards became infected in a certain time period.

Four hospitalized patients with severe heart failure were retrospectively included who had been infected with COVID-19 between January 7, 2020, and March 15, 2020, in the authors' department. All patients were transferred to an isolation ward since the diagnosis was confirmed or highly suspected. Three patients were suspected of having received hospital-related transmission because they were once in the same ward. None of the patients had fever during the illness, and they had just mild cough or fatigue at the time of diagnosis. Significantly enlarged left ventricle ([Figure 1](#fig1){ref-type="fig"} ) and reduced left ventricular ejection fraction were observed in 4 patients, and all had New York Heart Association functional class IV. Interestingly, Patient \#1 was had negative results for 2 consecutive nucleic acid tests but positive result for serum antibodies (immunoglobulin M \[IgM\] 69.12 AU/ml). Only 2 patients had typical ground-glass imaging changes on lung computed tomography scans ([Figure 1](#fig1){ref-type="fig"}). With exacerbations, Patient \#3 and \#4 were transferred to intensive care units, and both died 10 days after the first positive nucleic acid test result. Three patients had elevated troponin I (TNI) in the later period, especially in Patients \#3 and \#4, TNI increased significantly a few days before death. Moreover, the levels of C-reactive protein (CRP) and brain natriuretic peptide in patients 3 and 4 were significantly higher than those in the remaining 2 patients. It is also worth mentioning that testing results for patient 2 turned positive again after 2 consecutive negative test results for nucleic acid. The detailed information and treatment of patients are shown in [Table 1](#tbl1){ref-type="table"} .Figure 1Chest Radiography and Computed TomographyChest radiography and computed tomography of 4 end-stage heart failure patients with COVID-19.Table 1Characteristics of 4 Hospitalized End-Stage Heart Failure Patients Infected With COVID-19Patient \#1Patient \#2Patient \#3Patient \#4Demographics Age, yrs11385767 SexMaleMaleMaleMale DiagNosisMyocarditis, 10 yrs after TOF operationDCM, moderate MIDCM, severe MI, severe AISevere AS and AI, severe MI LVEDD (cm)5.57.210.88.5 LVEF (%)22262230 NYHA functional classIVIVIVIV Heart failure course1 month2 yrs5 yrs6 yrs ComorbiditiesTachycardiaVentricular arrhythmiaDiabetes, COPDHypertension, diabetes, ventricular premature beatConfirmation of COVID-1912-Mar19-Feb10-Feb14-FebSymptoms at onsetPoor appetite, fatigueCoughChest tightness, coughCough, sputumLaboratory findings White blood cell count (Normal range: 3.5-9.5 g/l)8.485.565.4012.18 Lymphocyte count (Normal range: 1.1-3.2 g/l)2.631.400.670.52 Lymphocyte% (Normal range: 20%-50%)31.025.212.44.3 CRP (Normal range: 8.0 mg/l)\<3.14\<3.14143103 First BNP (Normal range: 100 pg/ml)250.42,085.782,22.14,450.0 Latest BNP (Normal range: 100 pg/ml)109.8603.020,700\>5,000 First TNI (Normal range: 26.2 ng/l)48.69.5143.571.2 Latest TNI (Normal range: 26.2 ng/l)3.871.33,749.61,518.2 Plasma albumin (Normal range: 35-55 g/l)38.041.933.726.5 D-dimers (Normal range: 0.5 mg/l FEU)0.220.230.4720.02019nCoV nucleic acid test (throat swabs)Twice negativeTwice positiveTwice positiveTwice positive2019nCoV antibody (10 AU/ml)IgM 69.12NoNoNoCT findingsNo abNormalitiesMild infectious lesions in bilateral lungPatchy dense shadow and ground-glass changes in the lower lobe of bilateral lungMultiple ground-glass changes in bilateral pulmonary zoneAnti-heart failure drugs Beta-blockerYesYesYesYes DiureticsYesYesYesYes Sacubitril valsartan sodium tabletsNoYesYesYes Recombinant human BNPNoNoYesYes Intravenous inotropesYesNoYesYesAnti-COVID-19 treatment RibavirinNoNoYesNo AntibioticNoYesYesYes AbidolNoNoYesNo Interfero-αYesYesYesYes GlucocorticoidsNoNoNoNo Intravenous immune globinNoYesNoNo Oxygen supplyYesYesYesYesClinical course Intensive unit careNoNoYesYes ARDSNoNoYesYes Mechanical ventilationNoNoNoNo OutcomeUnder therapyUnder therapyDeathDeath[^1]

This study reported for the first time 4 end-stage heart failure patients who were infected with COVID-19, 2 with severe presentation and the others mild. These patients showed some similar characteristics as described in previous reports ([@bib3]). For instance, all 4 patients were male, consistent with previous findings that higher percentages of infection were found in men than in women. In addition, critically ill COVID-19 patients with heart failure also had typical lymphopenia and significantly increased CRP levels.

Patients with end-stage heart failure seemed to have a high mortality rate after infection with pneumonia. Older age, more comorbidities, poor general condition, and severe myocardial injury may be risk factors. The most novel finding was that the TNI levels of the 2 critically ill patients were 20-fold increased, indicating myocardial injury. Although there have been previous reports of myocardial damage in COVID-19 patients ([@bib4],[@bib5]), those reports chose mainly nonspecific indicators such as creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH), which could be confounded by many other factors in clinic. In addition, CK-MB and LDH were not, in fact, significantly increased in those reports. The present findings provided definitely stronger evidence of myocardial injury by COVID-19.

The exact mechanism of myocardial injury caused by 2019-nCoV is not completely clear, but through present and previous findings, it is clear that 2019-nCoV infection can cause myocardial injury and is closely related to disease progression. The study was limited by small sample size. Longitudinal studies in a larger cohort of heart failure patients would help to understand the prognosis of the disease.
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[^1]: ARDS = acute respiratory distress syndrome; BNP = brain natriuretic peptide; CRP = C-reactive protein; CT = computed tomography; FEU = fibrinogen equivalent units; IgM = immuNoglobulin M; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; TNI = troponin I.
